Actively Recruiting
Comparing Maternal Outcomes in Pregnant Women with Iron Deficiency Anemia Treated with Ferinject versus Venofer
Led by Western Galilee Hospital-Nahariya · Updated on 2026-09-11
200
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This research investigates maternal outcomes in pregnant women suffering from iron deficiency anemia with hemoglobin levels below 9 gdl. It compares the effects of two intravenous iron treatments, Venofer and Ferinject, focusing on the need for blood transfusions and hemoglobin levels before and after delivery. The study is designed as a Phase 4 interventional trial and aims to better understand how these treatments impact anemia in pregnancy. Participants are randomly assigned to one of two groups one receiving up to five doses of Venofer and the other receiving two weekly doses of Ferinject at 500 mg each. Both treatments are intravenous iron therapies intended to improve hemoglobin levels during pregnancy. The trial runs from November 2023 to December 2027, with primary assessments conducted at delivery and within 48 hours postpartum. During the study, women will be monitored for hemoglobin levels at delivery and shortly after birth to evaluate treatment effectiveness. Researchers will measure the proportion of women whose hemoglobin exceeds 11 gdl at delivery and their postpartum hemoglobin levels. Safety and maternal outcomes related to anemia treatment will be followed throughout the pregnancy period. Participants can expect regular assessments during their prenatal care and delivery hospitalization.
CONDITIONS
Brief Title
Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia
Research Team
M
maya Wolf, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here